Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

The Effect of Rifaximin on Portal Vein Thrombosis in Cirrhotic Patients

NCT03631147 is registered in ClinicalTrials.gov with Shanghai Zhongshan Hospital as lead sponsor.

NCT NCT03631147
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03631147 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
The Effect of Rifaximin on Portal Vein Thrombosis in Cirrhotic Patients
Lead sponsor
Shanghai Zhongshan Hospital
Phase
Not applicable
Overall status
Unknown status
Start date
September 3, 2018
Completion date
December 31, 2019
Enrollment
96 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

cirrhosis, portal vein thrombosis